Leveraging Real-World and Passive Data to Significantly Improve Site Satisfaction and Reduce Trial Costs
In the rapidly evolving landscape of clinical trials, data collection remains one of the most time-consuming and cost-intensive processes. For decades, the manual abstraction of clinical data into electronic case report forms (eCRFs) has been the predominant method for gathering information from trial participants. This paradigm, largely unchanged since the 1990s, remains resource- intensive and[…]
› READ THE BLOGPOSTERS
Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes
MAY 9, 2024
At ISPOR Annual 2024, Jessica Probst, MPH presented in the AI in HEOR poster tour on Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes. This poster was also a Top 5% Finalist for the ISPOR 2024 Research Presentation Awards. View the full poster >>
Real-World Characterization and Management of Alopecia Areata Patients in the U.S.
MAY 16, 2023
View our poster on Real-World Characterization and Management of Alopecia Areata Patients in the U.S. Click to view!
EBOOKS
2024 Data Insights
DEC 18, 2024
In 2024, AI revolutionized drug development in the broader pharmaceutical landscape. Companies increasingly integrated AI to accelerate research, optimize clinical trials, and personalize patient care. This trend underscores the growing importance of AI-driven solutions in enhancing patient treatment efficiencies and outcomes. OM1 is at the forefront of this transformation – our award-winning, patented AI-powered digital phenotyping[…]
Real-World Analytics: A Complimentary Suite of Analytic Reports
JUL 15, 2024
A complimentary suite of analytic reports for understanding the reasons behind medication discontinuation, patient outcomes, and prescribing behaviors. Introduction to Real-World Analytics Reasons for Discontinuation Report Comparative Outcomes Report Prescriber Trends Report Meet our Experts View the ebook >>
VIDEOS
PhenOM: AI Solutions
JUL 16, 2024
PhenOM® is an artificial intelligence (AI)-powered digital phenotyping platform trained using OM1’s repository of linked EMR, claims and other data covering more than 300 million patients. The richness of the source data lets these phenotypes capture many complex facets of the target patients’ journeys. View the video on YouTube >>
OM1 Aspen: Integrated Evidence Generation
JUL 16, 2024
OM1 Aspen leverages our proprietary data sourcing, processing and enrichment technologies, including electronic medical records harmonization, image management, advanced medical text processing and linkage, to deliver a more efficient, cost-effective and scalable approach to research. Tap into our networks or build new ones for automated evidence generation. Harness scientifically robust data from large and diverse[…]
NEWS & ARTICLES
Understanding the link between GLP-1 therapies and suicidal ideation using real-world data
MAY 21, 2025
Read the full article >> The Evidence Base May 19, 2025 In large clinical trials, glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated significant effectiveness in improving glycemic control and reducing cardiovascular risk. However, recent concerns have arisen following reports suggesting a potential association between GLP-1 receptor agonists and increased risk of suicidal ideation (SI) and[…]
OM1’s PhenOM® Foundation AI Surpasses One Billion Years of Health History in Model Training
MAY 13, 2025
Read the full press release >> BOSTON–(BUSINESS WIRE)–OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its[…]
WHITE PAPERS
Standardized Library of Asthma Outcome Measures
APR 10, 2025
April 2019 Significant variation exists in both the types and definitions of outcome measures used in patient registries, even within the same clinical area. This variation reduces the utility of registries, making it difficult to compare, link, and aggregate data across the spectrum of clinical care and reporting. To address these limitations, the Agency for[…]
Standardized Library of Atrial Fibrillation Outcome Measures
APR 10, 2025
November 2018 Significant variation exists in both the types and definitions of outcome measures used in patient registries, even within the same clinical area. This variation reduces the utility of registries, making it difficult to compare, link, and aggregate data across the spectrum of clinical care and reporting. To address these limitations, the Agency for[…]
WEBINARS
Navigating European PASS & HTA Requirements: Leveraging Data Automation for Post-Authorization Success
MAY 22, 2025
Register >> July 17, 2025 3PM CEST The European pharmaceutical landscape presents complex challenges in meeting Post-Authorization Safety Study (PASS) obligations and Health Technology Assessment (HTA) requirements. Successfully navigating these evolving regulations, especially with the implementation of the EU HTA Regulation, is crucial for sustained market access and demonstrating ongoing product value. Designed for pharmaceutical[…]
Predicting Response and Personalizing Treatment Decisions in Mental Health: New Opportunities with AI and Real-World Data
MAY 7, 2025
Register >> June 26, 2025 2:30pm ET Mental health conditions can take a significant toll on an individual—physically, socially, and financially. Despite new treatment options becoming available, many patients still continue to struggle with finding effective solutions. Frustratingly, even treatments with strong efficacy won’t work for everyone – and it’s very hard to know in advance[…]